In brief: Rockeby, C3, Heartware
Friday, 04 March, 2005
Rockeby Biomed Limited (ASX:RBY) is poised to launch its Candia5 candidiasis diagnostic in Europe, having received ISO certification and CE Mark approval for the product.
Clinical Cell Culture (C3, ASX:CCE) has notched up the first commercial sale of spray-on-skin technology, ReCell, to its Japanese distributor and the announced the first use of ReCell in Japan. C3 Chief Executive Officer Troels Jordansen said the company had invoiced over AUD$400,000 in the first quarter of the calendar year in Japan.
HeartWare (ASX:HTW) has appointed corporate lawyer David McIntyre as chief financial officer and company secretary.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
